We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) (LaFlavon)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01286909
Recruitment Status : Unknown
Verified February 2011 by Omicron Pharmaceuticals.
Recruitment status was:  Recruiting
First Posted : January 31, 2011
Last Update Posted : February 10, 2011
Information provided by:
Omicron Pharmaceuticals

Brief Summary:
A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).

Condition or disease Intervention/treatment Phase
Metabolic Disease Dietary Supplement: LaFlavon Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
Study Start Date : January 2011
Estimated Primary Completion Date : June 2011
Estimated Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Lycopene
U.S. FDA Resources

Arm Intervention/treatment
Experimental: LaFlavon Dietary Supplement: LaFlavon
two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
Other Name: Lycopene/Isoflavon
No Intervention: Placebo

Primary Outcome Measures :
  1. Increase in High-Density Lipoprotein (HDL) [ Time Frame: Change from Baseline in High-Density Lipoprotein (HDL) at 3 months ]

Secondary Outcome Measures :
  1. changes of liver enzymes [ Time Frame: Baseline and 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and Women with Metabolic Syndrome
  2. Elevated Triglycerides (> 150)
  3. Low High-Density Lipoprotein (HDL) (< 35)
  4. Willingness to take study nutritional supplement once a day for 3 months

Exclusion Criteria:

  1. Women who are pregnant, nursing, or who intend pregnancy during the period of treatment
  2. Known milk, soy or whey allergy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01286909

Contact: Dr. Akram Echtay, M.D. +9613856323
Contact: Sanan Sdepanian +9617098618 sanan_sdepanian@yahoo.com

Rafic Hariri University Hospital Recruiting
Beirut, Lebanon
Contact: Dr. Akram Echtaye, M.D.         
Principal Investigator: Dr. Akram Echtaye, M.D.         
Sponsors and Collaborators
Omicron Pharmaceuticals
Principal Investigator: Dr. Akram Echtay, M.D. Rafic Hariri University Hospital

Responsible Party: Dr. Akram Echtay, Omicron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01286909     History of Changes
Other Study ID Numbers: OP912011
First Posted: January 31, 2011    Key Record Dates
Last Update Posted: February 10, 2011
Last Verified: February 2011

Keywords provided by Omicron Pharmaceuticals:

Additional relevant MeSH terms:
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Radiation-Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents